Table 2.
HIV Viral Suppression in Pregnant WLHIV on Elvitegravir by Medication Groups
| All (n = 134) |
EVG Initiated Before Pregnancy & Continued Through Delivery (Group 1) (n = 68) | EVG Initiated During Pregnancy (Group 2) (n = 52) | EVG Discontinued During Pregnancy (Group 3) (n = 14) | P Value | 1 vs 2 | 1 vs 3 | 2 vs 3 | No. | |
|---|---|---|---|---|---|---|---|---|---|
| Entered pregnancy on ART | 89 (66.9) | 67 (100) | 9 (17.3) | 13 (92.9) | <.001 | <0.001 | 0.173 | <0.001 | 133 |
| CD4 < 200 initial visit | 19 (14.3) | 8 (11.8) | 9 (17.6) | 2 (14.3) | .632 | 0.520 | 0.677 | 1.000 | 133 |
| HIV viral load initial visit, copies/mL | <.001 | <0.001 | 0.134 | 0.017 | 134 | ||||
| <40 (undetectable) | 66 (49.3) | 52 (76.5) | 7 (13.5) | 7 (50.0) | |||||
| 41–200 | 7 (5.22) | 2 (2.94) | 4 (7.69) | 1 (7.14) | |||||
| 201–1000 | 7 (5.22) | 3 (4.41) | 3 (5.77) | 1 (7.14) | |||||
| >1000 | 54 (40.3) | 11 (16.2) | 38 (73.1) | 5 (35.7) | |||||
| HIV viral load at delivery, copies/mL | .194 | 0.115 | 0.217 | 0.892 | 134 | ||||
| <40 (undetectable) | 109 (81.3) | 60 (88.2) | 39 (75.0) | 10 (71.4) | |||||
| 41–200 | 12 (8.96) | 4 (5.88) | 6 (11.5) | 2 (14.3) | |||||
| 201–1000 | 1 (0.75) | 1 (1.47) | 0 (0.00) | 0 (0.00) | |||||
| >1000 | 12 (8.96) | 3 (4.41) | 7 (13.5) | 2 (14.3) | |||||
| Viral suppression at delivery | 109 (81.3) | 60 (88.2) | 39 (75.0) | 10 (71.4) | .094 | 0.099 | 0.205 | 0.744 | 134 |
Data are presented as No. (%).
Abbreviations: ART, antiretroviral therapy; EVG, elvitegravir; WLHIV, women living with HIV.